首页> 外文期刊>JAMA: the Journal of the American Medical Association >Resolving discrepancies between a meta-analysis and a subsequent large controlled trial.
【24h】

Resolving discrepancies between a meta-analysis and a subsequent large controlled trial.

机译:解决荟萃分析与后续大型对照试验之间的差异。

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: A recent meta-analysis found calcium supplementation to be highly effective in preventing preeclampsia but a large National Institutes of Health trial (Calcium for Preeclampsia Prevention [CPEP]) found no risk reduction due to calcium in healthy nulliparous women. OBJECTIVES: To resolve discrepancies between the results of the meta-analysis and the CPEP trial and to assess the role of effect heterogeneity in the discrepancies. DATA SOURCES: Literature search of English-language articles published prior to July 10, 1997, the date of publication of the CPEP trial, using MEDLINE and by a manual search of bibliographies of published articles. STUDY SELECTION: Trials were included if they reported data on preeclampsia and calcium supplementation. Fourteen trials were systematically evaluated for differences in study design and patient populations. One trial was excluded because its results were reported after publication of the major CPEP results. DATA EXTRACTION: The sample size and number of subjects who developed preeclampsia in the calcium supplementation group vs a control group were recorded and analyzed on an intent-to-treat basis. Each author independently extracted the data. DATA SYNTHESIS: Substantial heterogeneity existed across trials (P = .001). After stratifying studies by the presence of a placebo-controlled group and by high-risk and low-risk populations, the conclusions of the meta-analysis of placebo-controlled trials enrolling a low-risk population (relative risk, 0.79; 99% confidence interval, 0.44-1.42; P = .30) were compatible with the conclusions of the CPEP trial that calcium supplementation does not prevent preeclampsia in healthy nulliparous women. In contrast, the data implied a strong beneficial calcium effect (relative risk, 0.19; 99% confidence interval, 0.08-0.46; P = .001) in healthy high-risk subject populations. However, only 225 women were analyzed and because of inconsistent data, these results remain equivocal. CONCLUSIONS: Further studies are needed to establish the efficacy of calcium for preeclampsia prevention in healthy high-risk populations. A single summary measure does not adequately describe the findings of a meta-analysis when the observed effects in individual studies differ substantially. In such settings the primary focus should be to identify and incorporate pertinent covariates that reduce heterogeneity and allow for optimum treatment strategies.
机译:背景:最近的一项荟萃​​分析发现,补钙对预防先兆子痫非常有效,但一项大型的美国国立卫生研究院试验(预防先兆子痫的钙[CPEP])未发现健康的未产妇因钙引起的风险没有降低。目的:解决荟萃分析结果与CPEP试验之间的差异,并评估效应异质性在差异中的作用。资料来源:1997年7月10日(CPEP试验发表之日)之前使用MEDLINE检索的英语文章的文献检索,以及对已发表文章的书目进行手动检索的文献检索。研究选择:如果报告子痫前期和补钙数据,则包括试验。系统评价了14个试验的研究设计和患者人群的差异。排除了一项试验,因为其结果是在CPEP的主要结果公布后报告的。数据提取:记录钙补充组与对照组的子痫前期患者的样本量和人数,并进行意向性治疗分析。每个作者都独立提取数据。数据综合:各试验之间存在实质异质性(P = .001)。在根据安慰剂对照组和高风险和低风险人群的存在对研究进行分层之后,对安慰剂对照试验的荟萃分析得出了纳入低风险人群的结论(相对风险为0.79; 99%的置信度区间0.44-1.42; P = 0.30)与CPEP试验的结论相符,即补充钙不能预防健康的未产妇先兆子痫。相反,该数据表明,在健康的高风险受试者人群中,钙具有很强的有益钙效应(相对风险,0.19; 99%置信区间,0.08-0.46; P = .001)。但是,仅对225名妇女进行了分析,由于数据不一致,这些结果仍然模棱两可。结论:需要进行进一步的研究以建立钙在健康高危人群中预防先兆子痫的功效。当单个研究中观察到的效果有显着差异时,单一的汇总指标不足以描述荟萃分析的结果。在这种情况下,主要重点应该是识别和合并减少异质性并允许最佳治疗策略的相关协变量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号